Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
about
Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature reviewThe Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis.Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.Chondroprotective Effects and Mechanisms of Dextromethorphan: Repurposing Antitussive Medication for Osteoarthritis Treatment.Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases
P2860
Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Second-line biologic therapy o ...... s, and ankylosing spondylitis.
@ast
Second-line biologic therapy o ...... s, and ankylosing spondylitis.
@en
type
label
Second-line biologic therapy o ...... s, and ankylosing spondylitis.
@ast
Second-line biologic therapy o ...... s, and ankylosing spondylitis.
@en
prefLabel
Second-line biologic therapy o ...... s, and ankylosing spondylitis.
@ast
Second-line biologic therapy o ...... s, and ankylosing spondylitis.
@en
P2093
P1476
Second-line biologic therapy o ...... s, and ankylosing spondylitis.
@en
P2093
Andrea Becciolini
Carlotta Nannini
Delia Goletti
Emanuele Cassarà
Ennio Giulio Favalli
Fabrizio Cantini
Francesca Li Gobbi
Laura Niccoli
Marta Mosca
Maurizio Benucci
P356
10.1016/J.SEMARTHRIT.2017.03.008
P577
2017-03-22T00:00:00Z